Warning letters, 483s, Recalls, Import Alerts, Audit observations
Potential contamination of drug products with Diethylene Glycol(DEG), Ethylene Glycol(EG) has severe consequences including fatality
USFDA Warning letter to Glenmark cites deficiencies in Out of specification (OOS) investigations, firms response to
USFDA Warning letter to Dupont cites inadequate evaluation of complaints, even though the Firm received several
USFDA Warning letter to Dupont cites inadequate OOS investigations, Root cause and CAPA, Impact evaluation. The warning letter
USFDA Warning letter to Dupont cites failure to ensure test methods are suitable, use of Non
USFDA Warning letter to Dupont cites inadequate change management program. The warning letter to Dupont Nutrition USA in
USFDA Warning letter to Dupont, USA cites inadequate laboratory controls, integrity of data and quality system does
USFDA Warning letter to Centrient India (Toansa, Punjab FEI 3004497364) in December 2022 cite method
USFDA Warning letter to Centrient India (Toansa, Punjab FEI 3004497364) in December 2022 cited inadequate
USFDA Warning letter to Centrient India (Toansa, Punjab FEI 3004497364) in December 2022 cited deficiencies in investigating
